ArticleNPJ precision oncology2026
SQLE as a potential diagnostic and prognostic biomarker for LIHC: a multi-cohort and spatial study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver hepatocellular carcinoma (LIHC) remains a highly aggressive malignancy, necessitating novel biomarkers for early diagnosis and therapeutic intervention. This study investigates the role of Squalene epoxidase (SQLE), a key enzyme in cholesterol biosynthesis, in LIHC. Integrating multi-cohort analyses of nine GEO datasets and TCGA revealed significant upregulation of SQLE in LIHC tissues. These findings were corroborated at the proteomic level via multiplex immunohistochemistry (mIHC) on a tissue microarray of 48 paired clinical samples, where spatial analysis revealed a strong correlation between SQLE and the epithelial marker Pan Cytokeratin. Clinically, SQLE demonstrated potential diagnostic value and served as an independent prognostic factor for poor overall survival. Functional assays using shRNA knockdown in LIHC cell lines confirmed that SQLE inhibition decreased cellular proliferation, colony formation, and lateral migration. Mechanistically, elevated SQLE expression was associated with lipid metabolism modulation, m6A RNA modification, DNA damage responses, and an immunosuppressive tumor microenvironment. Notably, mIHC analysis of clinical TMAs revealed that high SQLE protein expression in tumor cells was significantly and negatively correlated with the infiltration of CD8 + T cells. Collectively, these results highlight SQLE as a promising diagnostic and prognostic biomarker that is associated with LIHC progression, potentially through metabolic and immunomodulatory pathways.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.